The IBM Registry at Yale

When retired Yale professor of economics Martin Shubik was diagnosed with inclusion body myositis (IBM) in 2003, very little was known about the disease. At the time, few professional resources had answers to simple questions like “What can I expect from this disease?”

Continue Reading
Mother and Daughter Hugging

Lenabasum in dermatomyositis clinical trial

Corbus Pharmaceuticals is now recruiting dermatomysitis patients for an exciting phase 3 clinical trial for lenabasum. The trial, known as DETERMINE, is designed to evaluate the efficacy and safety of lenabasum for the treatment of dermatomyositis.

Continue Reading
Mother and Daughter Hugging

Lenabasum questions answered

Excitement is building for Corbus Pharmaceutical’s Phase 3 clinical trial testing the safety and effectiveness of their new drug lenabasum in dermatomyositis patients.

Continue Reading